ArticleCancer immunology, immunotherapy : CII2026
Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab.
I-Wen Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.